體位性低血壓藥物市場－全球產業規模、佔有率、趨勢、機會及預測（按產品、診斷測試類型、最終用戶、地區和競爭格局分類，2021-2031年）

全球姿勢性低血壓治療市場預計將從 2025 年的 6.2219 億美元成長到 2031 年的 10.2693 億美元，複合年成長率為 8.71%。

該市場主要包括用於對抗站立時持續性血壓下降的藥物，這些藥物透過增強血管張力和增加血液容量來發揮作用。關鍵成長要素包括全球人口快速老化以及慢性自主神經神經病變（例如帕金森氏症和糖尿病）盛行率的不斷上升，這些疾病需要藥物治療來控制症狀。美國心臟協會強調了合併症與自主神經功能障礙之間的聯繫，並報告稱，到2025年，約47%的美國成年人將患有高血壓，這將推動對有效治療方法的臨床需求。

儘管成長指標令人鼓舞，但由於現有治療方法的安全隱患，特別是仰臥位高血壓的風險，市場仍面臨許多挑戰。仰臥位高血壓的特徵是患者仰臥時血壓急劇升高，迫使醫療機構採取劑量限制的治療方案，並將處方限制在重症病例中。因此，這些安全隱患限制了潛在患者群體，並促使人們依賴非藥物療法，阻礙了該領域治療藥物的更廣泛商業性發展。

市場促進因素

全球老年人口的快速成長是市場成長的主要驅動力。與老齡化相關的生理功能衰退，例如血管僵硬和壓力感受器敏感性降低，顯著增加了發生姿勢性低血壓的風險。這一變化導致人們迫切需要藥物治療來預防暈厥和跌倒，從而導致對血管加壓藥物的穩定需求。日本內務部在2024年9月發布的《統計專題》第143期中也印證了這一趨勢，報告稱65歲及以上人口將達到創紀錄的3625萬。這意味著大規模的老年人口易患自主神經功能障礙，迫使製造商擴大業務。

此外，包括神經源性體位性低血壓和糖尿病在內的合併症的增加，進一步凸顯了標靶藥物治療的必要性。由於慢性高血糖通常會損害自主神經系統並導致次發性神經病變，因此藥物治療對於確保患者的病情穩定和生活品質至關重要。根據世界衛生組織（WHO）2024年11月發布的新聞稿，全球糖尿病成人患者人數超過8.28億，構成了一個龐大的繼發性自主神經併發症高風險族群。此外，Theravance BioPharma在2024年指出，美國約有5萬人患有多重系統退化症症，這進一步強調了這個特定患者群體迫切的臨床需求。

市場挑戰

現有藥物的安全挑戰，尤其是臥位高血壓的風險，嚴重阻礙了全球體位性低血壓治療市場的商業性擴張。儘管現有療法能有效增加血管張力和血液容量以預防姿勢性低血壓，但其療效往往在患者臥位時仍然存在，可能導致靜止或睡眠期間出現危險的高血壓。這種生理矛盾迫使臨床醫師採取保守的給藥通訊協定，優先考慮安全性而非最大程度地緩解症狀，導致這些藥物的臨床價值相對降低。

因此，醫療機構不願開立這些強效藥物，導致目標患者群僅限於病情最嚴重的患者，從而限制了整體市場滲透率。這種謹慎的做法得到了近期臨床研究的支持。例如，美國心臟協會發現，到2025年，臥位高血壓與自主神經功能障礙患者發生中風和新發心臟衰竭的風險增加約兩倍有關。這種升高的心血管風險迫使醫療機構限制藥物使用，直接阻礙了市場創收能力。

市場趨勢

市面上一個重要的轉變是新型去甲腎上腺素再回收抑制劑）的研發，這類藥物能夠在持續控制症狀的同時，最大限度地降低與仰臥位高血壓相關的毒性風險。與需要頻繁給藥的傳統血管加壓藥物不同，這些先進的藥物能夠選擇性地抑制神經血管連接處的去甲腎上腺素再攝取，從而持續改善血管張力，並特異性地針對神經源性亞型。作為這項進展的典型例證，Theravance BioPharma公司在2025年8月的新聞稿中公佈了其3期CYPRESS試驗的結果，表明該公司正在開發amplexetine，以填補美國4萬名患有與多重系統退化症相關的症狀性神經源性體位性低血壓患者的關鍵治療空白。

同時，製藥業越來越重視超越症狀性血壓控制、著眼於潛在神經退化病理的緩解疾病療法。製藥公司正投資研發能夠抑制α-突觸核蛋白聚集的藥物，旨在改變自主神經功能障礙的臨床進程，而不僅僅是治療急性姿勢性低血壓。 Alterity Therapeutics公司正是這項轉變的例證。該公司在2025年1月的新聞稿中宣布，其在研藥物ATH434在早期多重系統退化症症患者中顯示出48%的臨床進展顯著減緩，凸顯了結合神經保護和血流動力學穩定作用的治療方法的巨大潛力。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球體位性低血壓藥物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 副產物（屈昔多巴、ludrocortisone、Indometacin、鹽酸Midodrine、非類固醇抗發炎藥、吡啶斯的明）
  • 依診斷檢驗類型（血液檢查、心電圖、心臟超音波圖、運動負荷試驗）
  • 依最終使用者（門診手術中心、診斷中心、醫院/診所）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美體位性低血壓藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲體位性低血壓藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區體位性低血壓藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲姿勢性低血壓藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美姿勢性低血壓藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球體位性低血壓藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Mylan NV
• Upsher-Smith Laboratories, LLC
• Chelsea Therapeutics International, Ltd
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• Apotex Inc
• Pfizer Inc.
• Novartis AG
• H. Lundbeck A/S
• Amneal Pharmaceuticals LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Orthostatic Hypotension Drugs Market is projected to expand from USD 622.19 Million in 2025 to USD 1026.93 Million by 2031, registering a CAGR of 8.71%. This market encompasses pharmaceutical agents formulated to counteract the sustained drop in blood pressure experienced upon standing, primarily by enhancing vascular tone or blood volume. Key growth drivers include a rapidly aging global population and a rising prevalence of chronic autonomic disorders like Parkinson's disease and diabetes, which require pharmacological solutions for symptom management. Highlighting the link between comorbidities and autonomic dysfunction, the American Heart Association reported in 2025 that nearly 47% of adults in the United States suffer from hypertension, fueling the clinical need for effective therapies.

Despite these favorable growth indicators, the market faces significant hurdles due to the adverse safety profiles of existing treatments, particularly the risk of supine hypertension. This condition, defined by dangerously elevated blood pressure while the patient is recumbent, forces medical providers to adopt restricted dosing regimens and limit prescriptions to only severe cases. Consequently, these safety concerns constrain the potential patient base and promote reliance on non-pharmacological management strategies, thereby hindering the broader commercial development of therapeutic agents in this sector.

Market Driver

The rapid expansion of the global geriatric demographic acts as a primary engine for market growth, as age-related physiological declines, such as vascular stiffening and diminished baroreceptor sensitivity, significantly increase susceptibility to orthostatic hypotension. This shift creates a critical need for pharmacological interventions to prevent syncope and falls, generating steady demand for vasopressor drugs. Underscoring this trend, the Ministry of Internal Affairs and Communications of Japan reported in September 2024 via 'Statistical Topics No. 143' that the population aged 65 and older hit a record 36.25 million, representing a massive group prone to autonomic dysfunction that compels manufacturers to scale operations.

Furthermore, the rising incidence of neurogenic orthostatic hypotension and comorbidities, especially diabetes, intensifies the need for targeted drug therapies. Chronic hyperglycemia often compromises the autonomic nervous system, resulting in secondary neuropathies that require medication to ensure patient stability and quality of life. According to a World Health Organization press release in November 2024, the global number of adults with diabetes has exceeded 828 million, creating a vast population susceptible to secondary autonomic complications. Additionally, Theravance Biopharma noted in 2024 that multiple system atrophy affects roughly 50,000 individuals in the United States, further emphasizing the urgent clinical demand from specific patient segments.

Market Challenge

The adverse safety characteristics of current pharmaceutical agents, particularly the risk of supine hypertension, present a substantial obstacle to the commercial expansion of the Global Orthostatic Hypotension Drugs Market. While current therapies effectively increase vascular tone or blood volume to prevent blood pressure drops during standing, they often remain active while patients are recumbent, causing dangerously high blood pressure during rest or sleep. This physiological conflict compels clinicians to utilize conservative dosing protocols that prioritize safety over maximum symptom relief, effectively diminishing the perceived clinical value of these medications.

As a result, provider reluctance to prescribe these potent drugs shrinks the addressable patient population to include only the most severe cases, thereby limiting overall market penetration. This cautious approach is supported by recent clinical findings; for instance, the American Heart Association identified in 2025 that supine hypertension is associated with a near two-fold increase in the risk of stroke and incident heart failure in patients with autonomic dysfunction. This elevated cardiovascular risk profile forces healthcare professionals to restrict pharmacological usage, which directly impedes the market's broader revenue capabilities.

Market Trends

A significant shift in the market is the development of novel norepinephrine reuptake inhibitors, designed to provide durable symptom management while minimizing the toxicity risks associated with supine hypertension. Unlike traditional vasopressors that necessitate frequent administration, these advanced agents deliver sustained vascular tone improvements by selectively inhibiting norepinephrine reuptake at the neurovascular junction, specifically targeting neurogenic subtypes. Highlighting this progress, Theravance Biopharma announced in an August 2025 press release regarding the 'Pivotal Phase 3 CYPRESS Study' that it had advanced ampreloxetine to fill a critical treatment gap for the 40,000 patients in the United States suffering from symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy.

Concurrently, the industry is increasingly prioritizing disease-modifying therapeutics that go beyond symptomatic blood pressure regulation to address underlying neurodegenerative pathologies. Pharmaceutical companies are investing in agents capable of inhibiting alpha-synuclein aggregation, aiming to alter the clinical course of autonomic dysfunction rather than merely treating acute hypotensive events. This evolution is illustrated by Alterity Therapeutics, which reported in a January 2025 press release that their investigational agent, ATH434, achieved a statistically significant 48% reduction in clinical progression among early-stage multiple system atrophy patients, underscoring the potential of treatments that combine neuroprotection with hemodynamic stability.

Key Market Players

• Mylan N.V.
• Upsher-Smith Laboratories, LLC
• Chelsea Therapeutics International, Ltd
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• Apotex Inc
• Pfizer Inc.
• Novartis AG
• H. Lundbeck A/S
• Amneal Pharmaceuticals LLC

Report Scope

In this report, the Global Orthostatic Hypotension Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Orthostatic Hypotension Drugs Market, By Product

• Droxidopa
• Fludrocortisone
• Indomethacin
• Midodrine Hydrochloride
• NSAIDs
• Pyridostigmine

Orthostatic Hypotension Drugs Market, By Diagnostics Test Type

• Blood Tests
• ECG
• Echocardiogram
• Stress Test

Orthostatic Hypotension Drugs Market, By End User

• Ambulatory Surgical Centers
• Diagnostic Centers
• Hospitals & Clinics

Orthostatic Hypotension Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Orthostatic Hypotension Drugs Market.

Available Customizations:

Global Orthostatic Hypotension Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Orthostatic Hypotension Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Droxidopa, Fludrocortisone, Indomethacin, Midodrine Hydrochloride, NSAIDs, Pyridostigmine)
  • 5.2.2. By Diagnostics Test Type (Blood Tests, ECG, Echocardiogram, Stress Test)
  • 5.2.3. By End User (Ambulatory Surgical Centers, Diagnostic Centers, Hospitals & Clinics)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Orthostatic Hypotension Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Diagnostics Test Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Orthostatic Hypotension Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Diagnostics Test Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Orthostatic Hypotension Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Diagnostics Test Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Orthostatic Hypotension Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Diagnostics Test Type
      • 6.3.3.2.3. By End User

7. Europe Orthostatic Hypotension Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Diagnostics Test Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Orthostatic Hypotension Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Diagnostics Test Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Orthostatic Hypotension Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Diagnostics Test Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Orthostatic Hypotension Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Diagnostics Test Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Orthostatic Hypotension Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Diagnostics Test Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Orthostatic Hypotension Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Diagnostics Test Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Orthostatic Hypotension Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Diagnostics Test Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Orthostatic Hypotension Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Diagnostics Test Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Orthostatic Hypotension Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Diagnostics Test Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Orthostatic Hypotension Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Diagnostics Test Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Orthostatic Hypotension Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Diagnostics Test Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Orthostatic Hypotension Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Diagnostics Test Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Orthostatic Hypotension Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Diagnostics Test Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Orthostatic Hypotension Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Diagnostics Test Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Orthostatic Hypotension Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Diagnostics Test Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Orthostatic Hypotension Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Diagnostics Test Type
      • 9.3.3.2.3. By End User

10. South America Orthostatic Hypotension Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Diagnostics Test Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Orthostatic Hypotension Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Diagnostics Test Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Orthostatic Hypotension Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Diagnostics Test Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Orthostatic Hypotension Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Diagnostics Test Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Orthostatic Hypotension Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Mylan N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Upsher-Smith Laboratories, LLC
• 15.3. Chelsea Therapeutics International, Ltd
• 15.4. Amgen Inc.
• 15.5. F. Hoffmann-La Roche Ltd
• 15.6. Apotex Inc
• 15.7. Pfizer Inc.
• 15.8. Novartis AG
• 15.9. H. Lundbeck A/S
• 15.10. Amneal Pharmaceuticals LLC

16. Strategic Recommendations

17. About Us & Disclaimer